Manipal Hospitals Q1 FY27: Revenue surges 38.1% to ₹3,091 Cr, EBITDA up 26.4%
Manipal Hospitals reported Q1 FY27 revenue of ₹3,091 Cr, up 38.1% YoY. EBITDA grew 26.4% to ₹749 Cr. PAT stood at ₹243 Cr. The company noted strong patient demand and growth in high-acuity specialties. An investor conference call is scheduled for August 21, 2026.
The announcement pertains to the quarterly financial results of a listed company, which are material information for investors and stakeholders. The strong growth figures and positive outlook are likely to have a significant impact on investor perception.
The company reported significant year-on-year growth in revenue and EBITDA, along with improved operational metrics and successful integration of acquired entities. The commentary from the CEO also reflects confidence in future growth.
Manipal Health Enterprises Limited (Manipal Hospitals) announced its financial results for the quarter ended June 30, 2026 (Q1 FY27), marking its first results announcement post-listing on August 5, 2026.
The company reported a strong operating performance with revenue from operations reaching ₹3,091 crore, a 38.1% year-on-year increase. EBITDA stood at ₹749 crore, reflecting a 26.4% year-on-year growth. Excluding a one-off gain of ₹15 crore in Q1 FY26, EBITDA growth was 29.7% year-on-year. Inpatient and outpatient volumes grew by 38.8% and 26.0% respectively. Occupancy improved by 290 basis points to 65.0%.
PAT was ₹243 crore. Excluding ₹89 crore of post-tax interest on the NCD raised for the Sahyadri acquisition, adjusted PAT grew 30.9% year-on-year. ARPOB, excluding Sahyadri, was ₹77,200 per day, up 8.7% year-on-year. The integration of Sahyadri Hospitals continued to support the network's performance, with Sahyadri recording 12.8% revenue growth and 18.7% EBITDA growth year-on-year.
High-acuity specialties, particularly Oncology and Orthopedics, were key growth drivers. The company also highlighted its investment in advanced clinical equipment and successful complex medical procedures across its network. The conference call to discuss these results is scheduled for August 21, 2026.
What to do with a filing like this
Manipal Health Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Manipal Health Enterprises Limited. Read the original for the full detail.